Weight regain after stopping GLP-1 drugs follows a predictable curve, analysis finds

A systematic review and meta-regression published in eClinicalMedicine estimates how weight comes back after people stop taking GLP-1 receptor agonists. One year after stopping, about 60% of the weight lost during treatment had been regained ^[1]. The review pooled 48 studies, and the regain curve itself was fitted using six randomized trials with a total of 3,236 participants ^[1].

The 60% figure refers to the weight a person lost while on treatment, not to total body weight. Someone who lost 40 pounds, on average across the pooled trials, would have regained about 24 pounds a year after stopping ^[1].

The paper describes the pattern as exponential rather than a straight line. Regain is fastest right after treatment ends and then slows, and the fitted curve has a half-life of about 23 weeks ^[1]. In practical terms, the model places most of the early regain in the months immediately after stopping, with the curve flattening thereafter ^[1].

The model projects a plateau at 75.3% of the weight lost during treatment. That means it estimates regain eventually levels off at roughly three-quarters of what had been lost, rather than a full return to the starting weight within the period the model covers ^[1].

Several details have not been reported. Regain broken out by individual drug, by dose, or by how long participants had taken treatment before stopping has not been reported ^[1]. Whether the same curve applies to people taking these medications for type 2 diabetes, or to people who stopped because of cost, side effects or supply problems, has not been reported either ^[1].

Why it matters for patients

The estimate gives a group-level picture of what stopping usually looks like. Weight loss from these drugs depends on continuing treatment, and this analysis found that a majority of the lost weight returns within a year for the average participant in the pooled trials ^[1].

Because these are averages from pooled trials, individual experiences vary. The analysis reports figures for groups, not a prediction for any one person, and some participants regained more or less than the average ^[1].

The review covers weight only. Whether regaining weight after stopping changes other outcomes, such as blood sugar, blood pressure, or heart and kidney risk, has not been reported in this analysis ^[1].

The analysis also does not test any strategy for limiting regain, such as tapering the dose, moving to a lower maintenance dose, or adding a structured diet and exercise program after stopping. No results from those approaches appear in this review ^[1].

What happens next

The review summarizes trials that have already been completed; it does not report new trial data of its own ^[1]. No follow-up analysis, updated version, or regulatory action tied to these findings has been announced ^[1].